GM-CSF in Hodgkin Disease

Abstract

Letters15 June 1992GM-CSF in Hodgkin DiseaseGeraldine P. Schechter, MDGeraldine P. Schechter, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-12-1033 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: I wish to call your attention to three errors in the otherwise excellent paper by Gulati and Bennett (1). Two are minor and involve the SI units for blood cell concentration values. The investigators, I am sure, meant 20 x 109/L (not 200 x 109/L) for the threshold for platelet transfusion and 80 g/L (not 80 g/dL) for the threshold for red cell transfusion (p. 178, column 2, paragraph 1).The third error is more substantive and concerns the drawing of Figure 2 (p. 179). The text states that the 32-month actuarial survivals of the granulocyte-macrophage colony-stimulating...Reference1. GulatiBennett SC. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992;116:177-82. LinkGoogle Scholar1. GulatiBennett SC. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992;116:177-82. LinkGoogle Scholar1. GulatiBennett SC. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992;116:177-82. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Geraldine P. Schechter, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGabexat 15 June 1992Volume 116, Issue 12_Part_1Page: 1033-1034KeywordsAttentionBlood cellsGranulocyte macrophage colony stimulating factorHodgkin lymphomaPlatelets ePublished: 1 December 2008 Issue Published: 15 June 1992 PDF downloadLoading ...